Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-girentuximab and Nivolumab in Advanced Clear Cell Renal Cell Carcinoma
NCT05239533Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2022
- Primary completion
- Mar 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of 177-Lu-DOTA-cG250 in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximal tolerated dose at 24 weeks and Overall Response Rate at 24 weeks. Started Feb 2022; status: active, not recruiting.
02
Drugs
177-Lu-DOTA-cG250
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05239533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239533.